Jhanelle E Gray Selected Research

Jhanelle E Gray Research Topics

Disease

41	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 11/2010
28	Neoplasms (Cancer) 01/2022 - 11/2010
14	Disease Progression 01/2022 - 11/2017
13	Lung Neoplasms (Lung Cancer) 10/2020 - 01/2013
6	Fatigue 01/2022 - 01/2018
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2019 - 01/2013
3	Nausea 01/2022 - 08/2018
3	Pneumonia (Pneumonitis) 01/2022 - 11/2017
3	Vomiting 11/2019 - 01/2018
3	Melanoma (Melanoma, Malignant) 01/2017 - 01/2013
2	Brain Neoplasms (Brain Tumor) 10/2020 - 06/2017
2	Chest Pain (Chest Pains) 01/2020 - 12/2019
2	Body Weight (Weight, Body) 12/2018 - 11/2017
2	Neoplasm Metastasis (Metastasis) 12/2018 - 11/2017
2	Adenocarcinoma of Lung 12/2018 - 12/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Fibrosarcoma 01/2020
1	Cough 12/2019
1	Triple Negative Breast Neoplasms 01/2019
1	Injection Site Reaction 12/2018
1	Carcinogenesis 11/2018
1	Anemia 01/2017
1	Neutropenia 12/2015
1	Pain (Aches) 12/2015
1	Thrombocytopenia (Thrombopenia) 12/2015

Drug/Important Bio-Agent (IBA)

10	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2015
9	durvalumabIBA 01/2022 - 11/2017
8	Tyrosine Kinase InhibitorsIBA 03/2022 - 11/2010
8	PlatinumIBA 10/2020 - 01/2016
6	ErbB Receptors (EGF Receptor)IBA 03/2022 - 11/2010
6	osimertinibIBA 01/2020 - 11/2018
5	pembrolizumabIBA 01/2022 - 02/2018
4	B7-H1 AntigenIBA 01/2021 - 11/2017
4	VaccinesIBA 03/2019 - 01/2013
3	Biomarkers (Surrogate Marker)IBA 06/2021 - 11/2013
3	Pharmaceutical PreparationsIBA 01/2020 - 01/2017
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 03/2014
3	Histone Deacetylase InhibitorsIBA 11/2019 - 03/2014
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2018
2	Neoplasm Antigens (Tumor Antigens)IBA 06/2021 - 03/2019
2	Pemetrexed (MTA)FDA Link 10/2020 - 12/2015
2	Anaplastic Lymphoma KinaseIBA 01/2020 - 01/2018
2	Gefitinib (Iressa)FDA Link 01/2020 - 01/2019
2	Glycoproteins (Glycoprotein)IBA 01/2019 - 11/2018
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2019
2	Mucin-1 (CA 15-3 Antigen)IBA 11/2018 - 01/2013
2	adavosertibIBA 01/2017 - 01/2016
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	RamucirumabIBA 01/2022
1	SteroidsIBA 01/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	spartalizumabIBA 01/2022
1	NivolumabIBA 01/2022
1	LigandsIBA 01/2022
1	Carbonic Anhydrase IXIBA 01/2021
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2020
1	Glycerol KinaseIBA 01/2020
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 11/2019
1	Vorinostat FDA Link 11/2019
1	thiamine triphosphorate (TTP)IBA 01/2019
1	AfatinibIBA 01/2019
1	Dasatinib (BMS 354825)FDA Link 01/2019
1	Chemokine CCL21IBA 12/2018
1	CD40 Ligand (CD40L)IBA 12/2018
1	AntiemeticsIBA 08/2018
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 10/2017
1	sacituzumab govitecanIBA 10/2017
1	Immunoconjugates (Immunoconjugate)IBA 10/2017
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2017
1	omaveloxoloneIBA 01/2017
1	Alkaline PhosphataseIBA 01/2017
1	TriterpenesIBA 01/2017
1	ProteomeIBA 01/2017
1	BI 2536IBA 01/2017
1	Platinum Compounds (Compounds, Platinum)IBA 01/2016
1	Phosphotransferases (Kinase)IBA 01/2016
1	Ranitidine (Zantac)FDA LinkGeneric 12/2015
1	Carboplatin (JM8)FDA LinkGeneric 12/2015
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2015
1	NVP-BKM120IBA 09/2015
1	Checkpoint Kinase 1IBA 03/2014

Therapy/Procedure

17	Therapeutics 01/2022 - 11/2010
12	Immunotherapy 01/2022 - 01/2013
11	Drug Therapy (Chemotherapy) 03/2019 - 07/2011
6	Chemoradiotherapy 01/2022 - 11/2017
3	Radiotherapy 01/2022 - 11/2017
1	Precision Medicine 01/2017
1	Adjuvant Chemotherapy 12/2016
1	Continuity of Patient Care 10/2016